60 related articles for article (PubMed ID: 5793351)
1. A systematic review of pathophysiology and management of familial hyperaldosteronism type 1 in pregnancy.
Sanga V; Seccia TM; Rossi GP
Endocrine; 2021 Oct; 74(1):5-10. PubMed ID: 34043182
[TBL] [Abstract][Full Text] [Related]
2. Clinical and Molecular Perspectives of Monogenic Hypertension.
Levanovich PE; Diaczok A; Rossi NF
Curr Hypertens Rev; 2020; 16(2):91-107. PubMed ID: 30963979
[TBL] [Abstract][Full Text] [Related]
3. Aldosterone and electrolyte balance in human hypertension.
Genest J; Nowaczynski W
J R Coll Physicians Lond; 1970 Oct; 5(1):77-86. PubMed ID: 4950461
[No Abstract] [Full Text] [Related]
4. Hypertension with aldosterone excess.
Brown JJ; Fraser R; Lever AF; Robertson JI
Br Med J; 1972 May; 2(5810):391-6. PubMed ID: 4554158
[No Abstract] [Full Text] [Related]
5. Glucocorticoid-remediable aldosteronism.
McMahon GT; Dluhy RG
Cardiol Rev; 2004; 12(1):44-8. PubMed ID: 14667264
[TBL] [Abstract][Full Text] [Related]
6. [Glucocorticoid responsive aldosteronism: our pediatric cases and presentation of concepts].
Igarashi Y; Imai M; Egi S; Kawato H; Suwa S
Nihon Rinsho; 1971 Mar; 29(3):939-51. PubMed ID: 4324175
[No Abstract] [Full Text] [Related]
7. Non-tumorous "primary" aldosteronism. I. Type relieved by glucocorticoid (glucocorticoid-remediable aldosteronism).
Salti IS; Stiefel M; Ruse JL; Laidlaw JC
Can Med Assoc J; 1969 Jul; 101(1):1-10. PubMed ID: 5793351
[No Abstract] [Full Text] [Related]
8. Non-tumorous "primary" aldosteronism: II. Type not relieved by glucocorticoid.
Salti IS; Ruse JL; Stiefel M; Delarue NC; Laidlaw JC
Can Med Assoc J; 1969 Jul; 101(1):11-6. PubMed ID: 5793350
[No Abstract] [Full Text] [Related]
9. Hypertension with inappropriate aldosterone stimulation.
Christlieb AR; Hickler RB; Lauler DP; Williams GH
N Engl J Med; 1969 Jul; 281(3):128-31. PubMed ID: 4307140
[No Abstract] [Full Text] [Related]
10. Dexamethasone-suppressible hyperaldosteronism.
New MI; Siegal EJ; Peterson RE
J Clin Endocrinol Metab; 1973 Jul; 37(1):93-100. PubMed ID: 4351777
[No Abstract] [Full Text] [Related]
11. Coexistence of different phenotypes in a family with glucocorticoid-remediable aldosteronism.
Fallo F; Pilon C; Williams TA; Sonino N; Morra Di Cella S; Veglio F; De Iasio R; Montanari P; Mulatero P
J Hum Hypertens; 2004 Jan; 18(1):47-51. PubMed ID: 14688810
[TBL] [Abstract][Full Text] [Related]
12. [Hypertension treatable with glucocorticoids: report of a case].
Montero J; Fardella C; Mosso L
Rev Med Chil; 1997 Nov; 125(11):1361-5. PubMed ID: 9609059
[TBL] [Abstract][Full Text] [Related]
13. ALDOSTERONE SECRETION RATE IN CONGENITAL ADRENAL HYPERPLASIA. A DISCUSSION OF THE THEORIES ON THE PATHOGENESIS OF THE SALT-LOSING FORM OF THE SYNDROME.
KOWARSKI A; FINKELSTEIN JW; SPAULDING JS; HOLMAN GH; MIGEON CJ
J Clin Invest; 1965 Sep; 44(9):1505-13. PubMed ID: 14332163
[No Abstract] [Full Text] [Related]
14. CORRELATION OF PLASMA ACTH CONCENTRATION WITH ADRENOCORTICAL RESPONSE IN NORMAL HUMAN SUBJECTS, SURGICAL PATIENTS, AND PATIENTS WITH CUSHING'S DISEASE.
NEY RL; SHIMIZU N; NICHOLSON WE; ISLAND DP; LIDDLE GW
J Clin Invest; 1963 Nov; 42(11):1669-77. PubMed ID: 14083159
[No Abstract] [Full Text] [Related]
15. Studies on new diuretic compounds: spirolactone and chlorothiazide.
BOLTE E; VERDY M; MARC-AURELE J; BROUILLET J; BEAUREGARD P; GENEST J
Can Med Assoc J; 1958 Dec; 79(11):881-8. PubMed ID: 13608362
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
